News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Akorn, Inc. (AKRN) And Hameln Pharmaceuticals gmbh Announce The Signing Of The Exclusive License And Supply Agreement For Two Orphan Drug NDA's: Calcium-DTPA And Zinc-DTPA


10/19/2005 5:12:13 PM

Akorn, Inc. (OTCBB:AKRN.OB) and Hameln Pharmaceuticals gmbh (Hameln), a leading private German pharmaceuticals company, today announced the signing of the Exclusive License and Supply Agreement for two Orphan Drug NDA's: Calcium-DTPA and Zinc-DTPA. Akorn and Hameln announced the signing of a Binding Term Sheet on October 20, 2004 and had agreed to enter into the License and Supply Agreement by November 30, 2004. The two drugs were approved on August 11, 2004 by the U.S. FDA, and are indicated as antidotes for the treatment of radioactive poisoning, specifically internal contamination with plutonium, americium, or curium. Akorn is currently in discussions with the U.S. Government to secure a purchase order to stockpile these two drugs in the event of a "dirty bomb" or any potential nuclear threat or accident. Akorn anticipates receipt of these drugs from Hameln in December 2004 and expects revenues to commence at that time.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES